Cell and Gene Therapy | Novartis

Story
Nov 21, 2024
Addressing unmet needs for inherited neuromuscular diseases
Media Release
Jun 17, 2022
Novartis announces Nature Medicine publication of Zolgensma data demonstrating age-appropriate milestones when treating children with SMA presymptomatically
Media Release
Jun 12, 2022
Novartis five-year Kymriah® data show durable remission and long-term survival maintained in children and young adults with advanced B-cell ALL
Media Release
May 28, 2022
FDA approves Novartis Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma
Story
May 27, 2022
How Emily’s act of bravery inspired a wave of continued innovation
Media Release
May 04, 2022
Novartis Kymriah® receives EC approval as first CAR-T cell therapy for adults with relapsed or refractory follicular lymphoma
Media Release
Mar 25, 2022
Novartis receives positive CHMP opinion for Kymriah® CAR-T cell therapy for adult patients with relapsed or refractory follicular lymphoma in Europe
Media Release
Mar 10, 2022
Novartis signs initial agreement with Carisma Therapeutics for the manufacturing of HER 2 targeted CAR-M cell therapy
Media Release
Dec 22, 2021
Novartis to acquire Gyroscope Therapeutics, adding a one-time gene therapy that could transform care for geographic atrophy, a leading cause of blindness
Media Release
Dec 13, 2021
Novartis announces T-Charge™, next-generation CAR-T platform with first-in-human data at ASH 2021
Media Release
Aug 24, 2021
Novartis provides update on BELINDA study investigating Kymriah® as second-line treatment in aggressive B-cell non-Hodgkin lymphoma
Media Release
Sep 21, 2021
Novartis übernimmt Arctos Medical und erweitert damit ihr Optogenetik-Portfolio, um Patientinnen und Patienten mit einem schwerem Verlust des Sehvermögens Gentherapien anbieten zu können